Assessment of CA 19-9 in Patients with Thyroid Malignancies

Abdel Allah, Amany Abbas; Yousef, Laila Mohamed; Youssif, Marwa Ashraf; ElRawey, Mohammed

doi:10.21608/smj.2025.380939.1563

Assessment of CA 19-9 in Patients with Thyroid Malignancies

Document Type : Original Article

Authors

¹ Department of Clinical Pathology,Faculty of Medicine, Sohag University.

² Department of Clinical Pathology, Faculty of Medicine, Sohag University.

³ Clinical Pathology Department, Sohag Oncology Center, Ministry of Health, Sohag, Egypt

⁴ Clinical Pathology, Sohag university

10.21608/smj.2025.380939.1563

Abstract

Background: Carbohydrate antigen 19-9 (CA 19-9) is a cell surface glycoprotein complex that is used as a tumor marker for pancreatic and biliary malignancies. Its significance in thyroid cancer is controversy. However some studies demonstrated that CA19-9 is expressed in both differentiated and anaplastic thyroid carcinomas.

Objectives: 1.The aim of this work was to investigate the relationship between levels of CA 19-9 and thyroid malignancies.

2. The relation between CA19-9 and prognosis of the disease.

Methods: This case-control study was carried out on 120 subjects; 40 healthy individuals as control (Group I), 40 patients with localized thyroid cancer (Group II) and 40 patients with metastatic thyroid cancer (Group III). CA19.9 was measured in all patients.

Results: Ca19-9 show significant increase in group II, III as compared to group I (P <0.001). There is significant increase in medullary and follicular thyroid cancer in group III as compared to group II (P= 0.002). CA19-9 with cut off (>11.1); showed 87.5% sensitivity, 100% specificity and 97.4% accuracy.

Conclusions: Elevation of CA19-9 with thyroid malignancy is a sign of bad prognosis which require special care of diagnosis and treatment to be capable of overcoming the serious illness.

Keywords